Boehringer Ingelheim Pharmaceuticals (BIP) investor relations material

Business performance and financial highlights

• Net sales reached EUR 27.8 billion in 2025, up 7.3% year-over-year, with both Human Pharma and Animal Health contributing to growth.

• Human Pharma net sales were EUR 22.7 billion (+7.4%), driven by Jardiance (EUR 8.8 billion, +8.7%) and Ofev (EUR 3.8 billion, +5%).

• Animal Health achieved EUR 4.9 billion in sales (+6.5%), with NexGard leading at EUR 1.4 billion (+8.5%).

• R&D and M&A investments totaled EUR 6.4 billion, representing 23% of revenues, with Human Pharma at 27% and Animal Health at 11%.

• Capital expenditures reached EUR 1.4 billion across 40 major projects, including significant investments in Germany, Japan, and the U.S.

Innovation, pipeline, and product launches

• Two new molecular entities, JASCAYD and HERNEXEOS, were launched in 2025, marking significant portfolio renewal.

• JASCAYD, for idiopathic and progressive pulmonary fibrosis, saw strong uptake and rapid approvals in China and the U.S.

• HERNEXEOS, for HER2-mutant non-small cell lung cancer, marked a return to oncology and received fast-track approval in the U.S.

• Over 80 projects are in the Human Pharma pipeline, with 2/3 having first-in-class potential; six new pivotal phase III trials were initiated.

• Key late-stage assets include survodutide for obesity and MASH, apecotrep for rare kidney diseases, and verducatib for bronchiectasis.

Animal Health business and R&D

• Animal Health saw robust growth across species and regions, supported by innovation in vaccines and parasiticides.

• VAXXITEK H5, a three-in-one poultry vaccine, received European approval; emergency use approvals were granted for screwworm treatments.

• Pipeline advances include Canine BeatAI (AI-powered stethoscope) and new therapies for equine insulin dysregulation and chronic pet diseases.

• R&D spend in Animal Health exceeded EUR 500 million, over 10% of sales, above industry average.

• The business is preparing for future generic competition for NexGard but expects to maintain strong brand loyalty.